Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

A Single-center, Open-label, Cohort Study of Surufatinib With or Without Immunotherapy in Patients With Advanced Colorectal Cancer Who Have Failed Front-line Antiangiogenic TKI Therapy

This is a single-center, open-label, cohort clinical study to investigate the efficacy and safety of surufatinib with or without immunotherapy in patients with advanced colorectal cancer who failed front-line anti-angiogenic TKI therapy.

Patients have to received at least a second-line standard therapy or cannot tolerate other treatments, and have previously failed anti-angiogenic TKIs therapy(including but not limited to: fruquintinib/regorafenib/anlotinib) / apatinib, and are resistant to treatment, disease progression, intolerable toxicity or no continued benefit as assessed by investigator after therapy).

Patients who met the eligibility criteria are randomized 1:2 into two cohorts (cohort 1: surufatinib, cohort 2: surufatinib plus immunotherapy) to receive treatment until disease progression, death, unacceptable toxicity, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest. The primary study endpoint was PFS(progression free survival).

Study Overview

• Status: Recruiting
• Conditions: Colorectal Neoplasms
• Intervention / Treatment: Drug: Chohort 1: Surufatinib; Drug: Chohort 2: Immunotherapy; Drug: Chohort 2: Surufatinib

• Study Type: Interventional
• Enrollment (Anticipated): 50
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Xu Huiting, M.D.; Phone Number: +86-15307176219; Email: 2891533@qq.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430079
      • Recruiting
      • Hubei Cancer Hospital
      • Contact: Xu Huiting, M.D,; Phone Number: +86-15307176219; Email: 2891533@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 76 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Informed consent has been signed；
• Age ≥ 18 years, ≤80 years；
• Histologically confirmed advanced colorectal cancer；
• Patients have to received at least a second-line standard therapy or cannot tolerate other treatments, and have previously failed anti-angiogenic TKIs therapy(including but not limited to: fruquintinib/regorafenib/anlotinib) / apatinib, and are resistant to treatment, disease progression, intolerable toxicity or no continued benefit as assessed by investigator after therapy)；
• ECOG 0-2；
• Life expectancy ≥ 12 weeks
• Patients must have adequate organ function；
• Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration.

Exclusion Criteria:

• Have previously received surufatinib or immunotherapy;
• Have received other systemic anti-tumor therapies within 2 weeks(eg.chemotherapy or radiotherapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy);
• Participating in other drug clinical trials within 4 weeks before recruited;
• Have received major surgery within 4 weeks;
• Patients had other malignant tumors in the past 5 years or at the same time (except for the cured skin basal cell carcinoma and cervical carcinoma in situ);
• Pleural effusion or ascites causing relevant clinical symptoms , including respiratory syndrome (dyspnea≥CTC AE grade 2)；
• Clinically significant electrolyte abnormality；
• Systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 90mmHg regardless of any antihypertensive drugs；
• Patient currently has any disease or condition that affects drug absorption, or the patient cannot take surufatinib orally；
• Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI；
• Have evidence or history of bleeding tendency within 3 months or thromboembolic events within 12 months before enrollment;
• Clinically significant cardiovascular disease;
• Active or uncontrolled serious infection (≥CTCAE grade 2 infection);
• Clinical uncontrolled active infections, including human immunodeficiency virus (HIV) infection, active hepatitis B / C (HBV DNA Positive[1×104 copies/mL or >2000 IU/ml], HCV RNA positive[>1×103 copies/mL]);
• Patients have untreated central nervous system metastasis；
• Patients have not recovered from all toxicities associated with prior anti-tumor therapy ,to acceptable baseline status, or a NCI CTCAE v5.0 Grade of 0 or 1, except for alopecia, lymphopenia, and neurotoxicity of grade ≤2 due to chemotherapeutic drugs;
• Pregnant or lactating women;
• Have received blood transfusion therapy, blood products and hematopoietic factors within 14 days;
• Proteinuria ≥ 2+ (1.0g/24hr);
• There are concomitant diseases (such as severe hypertension, diabetes, thyroid disease, active infection, etc.) that seriously endanger the safety of patients or affect the completion of the study, or any laboratory abnormalities that are not suitable for participating in the clinical trial according to the judgment of the researcher.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1: Surufatinib Monotherapy; Patients who met the eligibility criteria took Surufatinib 300mg qd, every 3 weeks as a cycle	Drug: Chohort 1: Surufatinib; Surufatinib 300mg, qd, every 3 weeks as a cycle
Experimental: Cohort 2: Surufatinib with immunotherapy; Patients who met the eligibility criteria took Surufatinib with immunotherapy: Surufatinib:250mg qd, every 3 weeks as a cycle Immunotherapy: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle	Drug: Chohort 2: Immunotherapy; Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle; Drug: Chohort 2: Surufatinib; Surufatinib 250mg, qd, every 3 weeks as a cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator	36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
overall survival (OS)	OS is the time from enrollment to death due to any cause.	36 months
objective response rate (ORR)	Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1.	36 months
disease control rate (DCR)	DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator	36 months
quality of life (QoL) assessed by the QLQ-C30	QoL was defined as specific questionnaires can be used to evaluate the daily living ability of patients, so as to evaluate the effect of anti-tumor drug treatment In clinical research	36 months
adverse events (AE)	overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use.	36 months

Collaborators and Investigators

• Sponsor: Hubei Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2022
• Primary Completion (Anticipated): January 1, 2024
• Study Completion (Anticipated): December 1, 2024

Study Registration Dates

• First Submitted: May 9, 2022
• First Submitted That Met QC Criteria: May 11, 2022
• First Posted (Actual): May 12, 2022

Study Record Updates

• Last Update Posted (Actual): November 9, 2022
• Last Update Submitted That Met QC Criteria: November 5, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: LCKY2021030

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No